Dysmenorrhoea affects up to 90% of menstruating women, with moderate to severe pain impacting 1 in 3 women’s daily function, productivity, and mental health.
Global Market Overview:
- Dysmenorrhoea therapeutics market: USD 10.9 billion (2024)
- Primary treatments today include NSAIDs and hormonal contraceptives
- Consumers increasingly seeking natural, non-hormonal, and non-opioid solutions
Unmet Needs:
- Natural, non-invasive options
- Better symptom management without hormonal impact
- Convenient, patient-friendly delivery (e.g. gummies)
EVE's first pharmaceutical product, Dyspro, is a clinically-informed pastille designed to address these gaps - it is currently in market.
.jpg)
By combining EVE's proprietary solubility IP with consumer-preferred formats like gummies and softgels, EVE is unlocking access to markets traditionally dominated by outdated delivery mechanisms.
Dyspro is a prescription only product. Speak to your GP or a prescriber for more information.
Evidence-based information and support for endometriosis and period pain.
